Brickell Biotech CFO resigns to fully commit to Edgewise Therapeutics
BOULDER — R. Michael Carruthers, the chief financial officer and head accountant for Brickell Biotech inc. (Nasdaq: BII), is resigning […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
Biotechnology boom
The COVID-19 pandemic — and its seemingly never-ending aftermath — has been a nightmare for commercial landlords of many different…
Brickell Biotech launches brand reset amid positioning pivot
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, has launched a new brand, logo and website as…
Edgewise Therapeutics reports continued successful drug trials, $17.4M loss in third quarter
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) reported continued successful drug trials in the third quarter of 2022 as the…
A new Foothills — again
FORT COLLINS — The new owners who want to revitalize midtown Fort Collins’ half-century-old Foothills mall say they envision “a…